drugset / Trial / NCT00538811

Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders

NCT00538811

Phase 2/3 Completed 40 enrolled Aga Khan University
RandomizedParallel-groupOpen-labelTreatment

Summary

When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amantadine Unknown 100 mg
Subject interferon gamma Protein / enzyme biologic 2 iu
Background Ribavirin Small molecule 800 mg
Background Ribavirin Small molecule 1200 mg
Background interferon alfa-2b Protein / enzyme biologic 3 iu